First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC)
Publication
, Conference
Rosenberg, JE; Flaig, TW; Friedlander, TW; Milowsky, MI; Srinivas, S; Petrylak, DP; Merchan, JR; Bilen, MA; Carret, A-S; Yuan, N; Sasse, C; Hoimes, CJ
Published in: SWISS MEDICAL WEEKLY
2020
Duke Scholars
Published In
SWISS MEDICAL WEEKLY
EISSN
1424-3997
ISSN
1424-7860
Publication Date
2020
Start / End Page
26S / 27S
Related Subject Headings
- General & Internal Medicine
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Rosenberg, J. E., Flaig, T. W., Friedlander, T. W., Milowsky, M. I., Srinivas, S., Petrylak, D. P., … Hoimes, C. J. (2020). First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC). In SWISS MEDICAL WEEKLY (pp. 26S-27S).
Rosenberg, J. E., T. W. Flaig, T. W. Friedlander, M. I. Milowsky, S. Srinivas, D. P. Petrylak, J. R. Merchan, et al. “First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC).” In SWISS MEDICAL WEEKLY, 26S-27S, 2020.
Rosenberg JE, Flaig TW, Friedlander TW, Milowsky MI, Srinivas S, Petrylak DP, et al. First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC). In: SWISS MEDICAL WEEKLY. 2020. p. 26S-27S.
Rosenberg, J. E., et al. “First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC).” SWISS MEDICAL WEEKLY, 2020, pp. 26S-27S.
Rosenberg JE, Flaig TW, Friedlander TW, Milowsky MI, Srinivas S, Petrylak DP, Merchan JR, Bilen MA, Carret A-S, Yuan N, Sasse C, Hoimes CJ. First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC). SWISS MEDICAL WEEKLY. 2020. p. 26S-27S.
Published In
SWISS MEDICAL WEEKLY
EISSN
1424-3997
ISSN
1424-7860
Publication Date
2020
Start / End Page
26S / 27S
Related Subject Headings
- General & Internal Medicine
- 3202 Clinical sciences
- 1103 Clinical Sciences